The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

Scientists from DZNE, University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease ...

The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.

A study by the (UPV/EHU) demonstrates that the drug WIN55,212-2 protects the brain and reverses early cognitive damage caused ...

A treatment that could potentially slow the progression of amyotrophic lateral sclerosis (ALS) is being studied at the Montreal Neurological Institute-Hospital ... “We see very early in the (disease) ...

Liam Virgo said having functional neurological disorder (FND) affected his ability to walk and talk and left him "isolated" A man who was left unable to walk or talk by a neurological disorder has ...

A man who was left unable to walk or talk by a neurological disorder has called for greater understanding of his condition after he was told to "get moving" by a GP. Liam Virgo, 22, was 13 when he ...

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.

The deal would allow J&J to gain access to Intra-Cellular's oral therapy, Caplyta, which is approved in the U.S. to treat schizophrenia and depressive episodes associated with bipolar disorder ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra ... boosting its presence in the market for brain disease treatments. The deal would help accelerate growth ...

When we hear these scenarios, one of our first thoughts is “potential eating disorder.” But if you’re like most medical professionals globally, you have little to no training in eating ...